

AMENDMENTS TO THE CLAIMS:

Kindly cancel claim 1, without prejudice, amend claims 3, 5, 8-20 and 22 and add new claim 23, as shown below.

This listing of claims will replace all prior versions and listings of claims in the Application:

Claims 1-2 (cancelled)

Claim 3 (currently amended): A pharmaceutical delivery package according to claim [[1]]24, wherein said membrane comprises an alkali-dissolvable or acid-dissolvable material.

Claim 4 (cancelled)

Claim 5 (currently amended): A pharmaceutical delivery package consisting of fixed unit dose quantities of two or more different powdered pharmaceutical ingredients separated from one another on an ingestible membrane which forms a single delivery package, wherein said ingestible membrane has selected permeability porosity to fluids for controlled release of said powdered pharmaceutical ingredients at two or more different selected sites within the stomach or intestines of a patient's alimentary canal, further comprising [[an]] a mucosal adhesive layer on an outer surface of the membrane.

Claim 6 (previously presented): A pharmaceutical delivery package according to claim 5, wherein the adhesive is acid or alkaline activatable.

Claim 7 (original): A pharmaceutical delivery package according to claim 5, and further comprising an alkali or acid dissolvable membrane covering the adhesive.

Claim 8 (currently amended): A pharmaceutical delivery package according to claim [[1]]5, wherein said membrane comprises a material which expands upon contact with acid or alkaline in the alimentary canal, whereby to become more porous.

Claim 9 (currently amended): A pharmaceutical delivery package according to claim [[1]]5, wherein said membrane is formed into a tablet or capsule.

Claim 10 (currently amended): A pharmaceutical delivery package according to claim [[1]]5, wherein said powdered pharmaceutical ingredients are segregated from one another in a compartmentalized capsule.

Claim 11 (currently amended): A pharmaceutical delivery package according to claim [[1]]5, wherein said powdered pharmaceutical ingredients are segregated from one another in a tablet.

Claim 12 (currently amended): A pharmaceutical delivery package according to claim [[1]]5, wherein said powdered pharmaceutical ingredients are encapsulated within inert coatings.

Claim 13 (currently amended): A pharmaceutical delivery package according to claim [[1]]5, comprising a mixture of Ketoconazole and testosterone.

Claim 14 (currently amended): A pharmaceutical delivery package according to claim [[1]]5, comprising a mixture of Valacylovir and one or both of Cimetidine and Probenecid.

Claim 15 (currently amended): A pharmaceutical delivery package according to claim [[1]]5, comprising a mixture of Enalapril and a beta-adrenergic blocking agent, methyldopa, nitrate, a calcium blocking agent, hydrazinc, Prazosin or Digoxin.

Claim 16 (currently amended): A pharmaceutical delivery package according to claim [[1]]5, comprising a mixture of Omeprazole and B12.

Claim 17 (currently amended): A pharmaceutical delivery package according to claim [[1]]5, comprising a mixture of Omeprazole and Clarithromycin.

Claim 18 (currently amended): A pharmaceutical delivery package according to claim [[1]]5, comprising a mixture of Tamoxifen and a diuretic.

Claim 19 (currently amended): A pharmaceutical delivery package according to claim [[1]]5, comprising a mixture of Isotretinoin and an oral contraceptive.

Claim 20 (currently amended): A pharmaceutical delivery package according to claim [[1]]5, comprising a mixture of Metformin HCl and Sulfonylurea.

Claim 21 (previously presented): A controlled release pharmaceutical delivery package consisting of fixed unit dose quantities of two or more different powdered pharmaceutical ingredients combined in a single delivery package, wherein said delivery package comprises an ingestible membrane, and said two or more different powdered pharmaceutical ingredients comprise combinations of active pharmaceutical ingredients selected from the group consisting of (a) a mixture of Ketoconazole and testosterone, (b) a mixture of Valacylovir and one or both of Cimetidine and Probenecid, (c) a mixture of Enalapril and a beta-adrenergic blocking agent, methyldopa, nitrate, a calcium blocking agent, hydrazinc, Prazosin or Digoxin, (d) a mixture of Omeprazole and B12, (e) a mixture of Tamoxifen and a diuretic, (f) a mixture of Isotretinoin and an oral contraceptive, and (g) a mixture of Metformin HCl and Sulfonylurea, further comprising an adhesive on an outer surface of the membrane.

Claim 22 (currently amended): A pharmaceutical delivery package consisting of fixed unit dose quantities of two or more different powdered pharmaceutical ingredients separated from one another on an ingestible membrane which forms a single delivery package, wherein said ingestible membrane has selected permeability porosity to fluids for controlled release of said powdered pharmaceutical ingredients at a selected site or sites within a patient's alimentary canal ~~canal~~,

wherein said two or more powdered pharmaceutical ingredients are deposited on said membrane, separated from one another by one or more barriers or membranes, and wherein said two or more powdered pharmaceutical ingredients are selected from the group consisting of (a) a mixture of Ketoconazole and testosterone, (b) a mixture of Valacylovir and one or both of Cimetidine and Probenecid, (c) a mixture of Enalapril and a beta-adrenergic blocking agent, methyldopa, nitrate, a calcium blocking agent, hydrazinc, Prazosin or Digoxin, (d) a mixture of Omeprazole and B12, (e) a mixture of Tamoxifen and a diuretic, (f) a mixture of Isotretinoin and an oral contraceptive, and (g) a mixture of Metformin HCl and Sulfonylurea.

Claim 23 (new): A pharmaceutical delivery package consisting of fixed unit dose quantities of two or more different powdered pharmaceutical ingredients separated from one another on an ingestible membrane which forms a single delivery package, wherein said ingestible membrane has selected permeability porosity to fluids for controlled release of said powdered pharmaceutical ingredients at two or more different selected sites within a patient's alimentary canal,

wherein said two or more powdered pharmaceutical ingredients are deposited on said membrane, separated from one another by one or more barriers or membranes, and wherein said two or more powdered pharmaceutical ingredients are selected from the group consisting of Ketoconazole and testosterone; Valacylovir and one or both of Cimetidine and Probenecid; Enalapril and a beta-adrenergic blocking agent, methyldopa, nitrate, a calcium blocking agent, hydrazinc, Prazosin or Digoxin; Omeprazole and B12; Tamoxifen and a diuretic; Isotretinoin and an oral contraceptive; and Metformin HCl and Sulfonylurea.

HAYES SOLOWAY P.C.
130 W. CUSHING STREET
TUCSON, AZ 85701
TEL. 520.882.7623
FAX. 520.882.7643

175 CANAL STREET
MANCHESTER, NH 03101
TEL. 603.668.1400
FAX. 603.668.8567